These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 32066910)

  • 21. Experience with a two-tier reflex gFOBT/FIT strategy in a national bowel screening programme.
    Fraser CG; Digby J; McDonald PJ; Strachan JA; Carey FA; Steele RJ
    J Med Screen; 2012 Mar; 19(1):8-13. PubMed ID: 22156144
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Longitudinal Adherence to Immunochemical Fecal Occult Blood Testing vs Guaiac-based FOBT in an Organized Colorectal Cancer Screening Program.
    Benito L; Travier N; Binefa G; Vidal C; Espinosa J; Milà N; Garcia M
    Cancer Prev Res (Phila); 2019 May; 12(5):327-334. PubMed ID: 30890542
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia.
    Smith A; Young GP; Cole SR; Bampton P
    Cancer; 2006 Nov; 107(9):2152-9. PubMed ID: 16998938
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High test positivity and low positive predictive value for colorectal cancer of continued faecal occult blood test screening after negative colonoscopy.
    Brown JP; Wooldrage K; Wright S; Nickerson C; Cross AJ; Atkin WS
    J Med Screen; 2018 Jun; 25(2):70-75. PubMed ID: 28467146
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Factors affecting compliance in faecal occult blood testing: a cluster randomized study of the faecal immunochemical test versus the guaiac faecal occult test.
    Birkenfeld S; Belfer RG; Chared M; Vilkin A; Barchana M; Lifshitz I; Fruchter D; Aronski D; Balicer R; Niv Y; Levi Z
    J Med Screen; 2011; 18(3):135-41. PubMed ID: 22045822
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparative study of faecal occult blood kits in a colorectal cancer screening program in a cohort of healthy construction workers.
    Shuhaibar M; Walsh C; Lindsay F; Lee N; Walsh P; O'Gorman P; Boran G; McLoughlin R; Qasim A; Breslin N; Ryan B; O'Connor H; O'Morain C
    Ir J Med Sci; 2011 Mar; 180(1):103-8. PubMed ID: 20953981
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potential for prevention: a cohort study of colonoscopies and removal of adenomas in a FIT-based colorectal cancer screening programme.
    Larsen MB; Njor SH; Jensen TM; Ingeholm P; Andersen B
    Scand J Gastroenterol; 2019 Aug; 54(8):1008-1014. PubMed ID: 31397598
    [No Abstract]   [Full Text] [Related]  

  • 28. Guaiac faecal occult blood test performance at initial and repeat screens in the English Bowel Cancer Screening Programme.
    Kearns B; Whyte S; Chilcott J; Patnick J
    Br J Cancer; 2014 Oct; 111(9):1734-41. PubMed ID: 25180767
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Harms, benefits and costs of fecal immunochemical testing versus guaiac fecal occult blood testing for colorectal cancer screening.
    Goede SL; Rabeneck L; van Ballegooijen M; Zauber AG; Paszat LF; Hoch JS; Yong JH; Kroep S; Tinmouth J; Lansdorp-Vogelaar I
    PLoS One; 2017; 12(3):e0172864. PubMed ID: 28296927
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Colorectal cancer screening with the addition of flexible sigmoidoscopy to guaiac-based faecal occult blood testing: a French population-based controlled study (Wintzenheim trial).
    Denis B; Gendre I; Aman F; Ribstein F; Maurin P; Perrin P
    Eur J Cancer; 2009 Dec; 45(18):3282-90. PubMed ID: 19665368
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fecal-based colorectal cancer screening among the uninsured in northern Manhattan.
    Hillyer GC; Schmitt KM; Freedberg DE; Kramer RA; Su Y; Rosenberg RM; Neugut AI
    Am J Prev Med; 2014 Aug; 47(2):182-7. PubMed ID: 24951037
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Short term outcomes of the first round of a pilot colorectal cancer screening programme with guaiac based faecal occult blood test.
    Denis B; Ruetsch M; Strentz P; Vogel JY; Guth F; Boyaval JM; Pagnon X; Ebelin JF; Gendre I; Perrin P
    Gut; 2007 Nov; 56(11):1579-84. PubMed ID: 17616542
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interval cancers using a quantitative faecal immunochemical test (FIT) for haemoglobin when colonoscopy capacity is limited.
    Digby J; Fraser CG; Carey FA; Lang J; Stanners G; Steele RJ
    J Med Screen; 2016 Sep; 23(3):130-4. PubMed ID: 26589788
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transition to quantitative faecal immunochemical testing from guaiac faecal occult blood testing in a fully rolled-out population-based national bowel screening programme.
    Clark G; Strachan JA; Carey FA; Godfrey T; Irvine A; McPherson A; Brand J; Anderson AS; Fraser CG; Steele RJ
    Gut; 2021 Jan; 70(1):106-113. PubMed ID: 32234803
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of once-only flexible sigmoidoscopy screening on the outcomes of subsequent faecal occult blood test screening.
    Brown JP; Wooldrage K; Kralj-Hans I; Wright S; Cross AJ; Atkin WS
    J Med Screen; 2019 Mar; 26(1):11-18. PubMed ID: 30282520
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Faecal immunochemical tests to triage patients with lower abdominal symptoms for suspected colorectal cancer referrals in primary care: a systematic review and cost-effectiveness analysis.
    Westwood M; Corro Ramos I; Lang S; Luyendijk M; Zaim R; Stirk L; Al M; Armstrong N; Kleijnen J
    Health Technol Assess; 2017 May; 21(33):1-234. PubMed ID: 28643629
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of Colorectal Neoplasia in a Cohort Before and After the Change of Fecal Occult Blood Test in a French Colorectal Cancer Screening Program.
    Koïvogui A; Mab GL; Benamouzig R
    Am J Gastroenterol; 2018 Dec; 113(12):1891-1899. PubMed ID: 30337703
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lower risk of advanced neoplasia among patients with a previous negative result from a fecal test for colorectal cancer.
    Denters MJ; Deutekom M; Bossuyt PM; Stroobants AK; Fockens P; Dekker E
    Gastroenterology; 2012 Mar; 142(3):497-504. PubMed ID: 22108194
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The association between organised colorectal cancer screening strategies and reduction of its related mortality: a systematic review and meta-analysis.
    Ding H; Lin J; Xu Z; Wang HHX; Huang L; Huang J; Wong MCS
    BMC Cancer; 2024 Mar; 24(1):365. PubMed ID: 38515013
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Men with negative results of guaiac-based fecal occult blood test have higher prevalences of colorectal neoplasms than women with positive results.
    Brenner H; Hoffmeister M; Birkner B; Stock C
    Int J Cancer; 2014 Jun; 134(12):2927-34. PubMed ID: 24374771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.